We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Siemens Healthineers

Provides customized electronic systems and advanced imaging, diagnostics, therapy, and healthcare IT solutions for th... read more Featured Products: More products

Download Mobile App

Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019

By LabMedica International staff writers
Posted on 31 Jan 2019
Print article
Image: The Atellica Solution series of immunoassay and chemistry analyzers (Photo courtesy of Siemens Healthineers).
Image: The Atellica Solution series of immunoassay and chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) showcased its wide portfolio of products and services in its core areas of laboratory diagnostics and molecular medicine at MedLab Middle East 2019. MedLab is the only medical laboratory industry event that offers manufacturers the opportunity to meet a diverse audience of buyers. From distributors to senior end-users, the 2019 edition welcomed over 19,610 medical lab and trade professionals in search of the latest innovations.

At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The company demonstrated how the Atellica Solution delivers even more control and simplicity for labs with revolutionary sample-management possibilities. The company also promoted its Atellica Solution Assays having of an expanding menu of over 175 assays powered by proven detection technologies. Also on display at the event was Siemens’ Aptio Automation, the total lab automation leader to optimize clinical operations.

Additionally, Siemens highlighted its wide range of assays, including the Atellica IM and ADVIA Centaur high-sensitivity troponin I assay which provide fast, accurate, actionable troponin I results to aid in the diagnosis of acute MI; the Atellica IM and ADVIA Centaur enhanced liver fibrosis test, a minimally invasive blood test with results that correlate to the level of liver fibrosis severity assessed by liver biopsy; the Atellica IM and ADVIA Centaur B·R·A·H·M·S Procalcitonin (PCT) assay which helps achieve earlier sepsis diagnosis and risk assessment to help improve patient outcomes with high low-end sensitivity; and the Atellica IM and ADVIA Centaur vitamin D total assay which helps evaluate the total amount of 25-hydroxy-vitamin D (both D2 and D3) in the blood to provide patients with accurate results, regardless of level and whether or not they are supplemented over-the-counter or by prescription.

Siemens also highlighted its range of point-of-care analyzers, including the epoc blood analysis system which offers complete blood gas and basic metabolic panel with hematocrit and lactate on a single room temperature-stable test card; the Xprecia Stride coagulation analyzer for PT/INR testing that provides high usability and lab-accurate results at the point-of-care; and the Atellica 1500 automated urinalysis system which combines fully automated urine sediment and chemistry analyzers into one streamlined system.

In the field of molecular diagnostics, Siemens demonstrated the Fast Track cycler for molecular testing that uses magnetic induction technology for robust and reliable results, and Syndromic real-time PCR multiplexing assays, one of the largest ranges of syndromically grouped real-time PCR multiplex assays covering the major infectious-disease groups.

Siemens also presented its digital healthcare solutions, including the Atellica Process Manager to operationalize processes with centralized oversight and advanced analytics; Atellica Data Manager to operationalize lab data with open, scalable test-, QC-, and result-management software; the Atellica Inventory Manager to analyze and automate inventory to reduce costs and save time; the POCcelerator Data Management System which is an open POC Informatics solution that can aggregate data from 180+ device models available from more than 40 different vendors; and the FastFinder Software, a fully automated real-time PCR interpretation platform that is compatible with select kits from Fast Track Diagnostics.

Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
Silver Supplier
Real-Time PCR Thermal Cycler
Eonis Q96
Clostridium Difficile Test
Simplexa C. difficile Direct Kit
Fecal Bacterial Test
CLART EnteroBac

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more


view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.